Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is set to present new findings at the Alzheimer's Association International Conference $(AAIC)$ 2025 in Toronto. The presentations will include a cost savings analysis of the use of pTau217 as a screening tool in the company's Phase 2 ALTITUDE-AD trial of the therapeutic agent sabirnetug, as well as a nonclinical study on sabirnetug's selectivity for targeting amyloid beta oligomers (AβOs) compared to amyloid beta monomers. These results will be shared during poster presentations scheduled for July 28 and July 29, 2025, respectively. The studies emphasize sabirnetug's potential efficacy in treating early Alzheimer's disease and its distinct selectivity for toxic AβOs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.